He says all 15 clocks showed less aging than the time that passed in 71 people over 72 weeks, with two reaching significance. He calls it early and unproven.
Recap by typeshit. Post by @afshineemrani on X.
The review looks at concerns about misuse as demand for GLP-1 drugs grows, and points to how little evidence guides their use beyond approved conditions.
Researchers found self-reported GLP-1 use climbed from March 2024 to October 2025, mostly for weight loss, through channels insurance data may not capture.
The study is looking for women with hot flashes and night sweats and a BMI above 30. Mayo Clinic has the full eligibility rules and how to sign up.
A matched cohort study in Inflammatory Bowel Diseases found remission odds nearly six times higher on GLP-1 drugs, and weight loss alone didn't explain it.
The cookie chain built on oversized treats faces added pressure from Ozempic and Wegovy, with surveys pointing to changing snack habits among users.
EMY reports the FDA has added a fresh warning covering Wegovy and similar weight loss drugs. Tap through for what the label change says.
Loading…